scholarly journals AN IN VITRO STUDY OF CINNAMOMUM ZEYLANICUM AS NATURAL INHIBITOR OF ANGIOTENSIN-CONVERTING ENZYME (ACE) ON SHEEP (OVIS ARIES) TISSUES

2016 ◽  
Vol 9 (5) ◽  
pp. 249
Author(s):  
Ranjini Hs ◽  
Padmanabha Udupa Eg ◽  
Shobha U Kamath ◽  
Manjunath Setty ◽  
Basavaraj Hadapad ◽  
...  
Keyword(s):  
Cardiovascular Diseases ◽  
Angiotensin Converting Enzyme ◽  
Methanolic Extract ◽  
Enzyme Inhibitor ◽  
Ovis Aries ◽  
Converting Enzyme ◽  
Kinetic Assay ◽  
Natural Inhibitor ◽  
Ace Activity

ABSTRACTObjective: The present study was aimed to find the angiotensin-converting enzyme (ACE) inhibitory activity using the methanolic extract ofCinnamomum zeylanicum (as a natural inhibitor) on sheep tissues as the enzyme source.Methods: Hippuryl-histidyl-leucine (HHL) as a substrate, tissue ACE activity was measured spectrophotometrically at 228 nm. For an incubationperiod of 30 minutes at 37°C, the linearity of ACE activity of kidney, lung, and testis enzyme was established. A known medicinal plant C. zeylanicumwas used as natural inhibitor of ACE. In this enzyme assay, inhibitory effect of methanolic extract of C. zeylanicum on kidney, lung and testicular ACEwas determined. ACE activity was confirmed by captopril, a standard inhibitor of ACE.Results: In the presence of a methanolic extract of C. zeylanicum (10:1), ACE activity was determined and this has inhibited ACE activity verysignificantly. C. zeylanicum leaves extract has reduced sheep kidney, lung, and testis ACE activity by 70.06%, 12.63%, and 20.23%, respectively.Conclusion: Significant inhibition was observed in the kidney ACE than in lung and testis ACE activity. This can propose that there may be a possiblerole in controlling blood pressure or reduction in cardiovascular diseases. Some plants with the great medicinal property may be considered aspromising sources of natural inhibitors of ACE for medicine and commercial uses. This comprehensive study may show numerous beneficial effects asa potential therapeutic agent for lowering blood pressure.Keywords: Angiotensin-converting enzyme, Natural angiotensin-converting enzyme inhibitor, Kinetic assay, Hippuryl-histidyl-leucine, Cinnamomumzeylanicum, Cardiovascular diseases.

Angiotensin-converting enzyme determination in plasma during therapy with converting enzyme inhibitor: two methods compared

1991 ◽  
Vol 37 (8) ◽  
pp. 1390-1393 ◽  
Author(s):  
T P Gorski ◽  
D J Campbell
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Spectrophotometric Method ◽  
Enzyme Inhibitor ◽  
Ang Ii ◽  
Converting Enzyme ◽  
Fluorometric Method ◽  
Converting Enzyme Inhibitor ◽  
Ace Activity

Abstract For normal and above-normal concentrations of angiotensin-converting enzyme (ACE; EC 3.4.15.1) activity in plasma, results of a manual fluorometric method [with hippuryl-histidyl-leucine (HHL), 5 mmol/L, as substrate] correlated well with those of an automated spectrophotometric method [with 3-(2-furylacryloyl)-L-phenylalanyl-glycyl-glycine (FAPGG), 2 mmol/L, as substrate]. However, for patients receiving converting enzyme inhibitor (CEI) therapy, the spectrophotometric method showed much greater suppression of plasma ACE activity than did the fluorometric method. To determine which of the two methods provided a more reliable indication of ACE inhibition in vivo, we measured plasma ACE, angiotensin I (ANG I), and angiotensin II (ANG II) in patients receiving the CEI perindopril. During perindopril therapy, changes in the ratio of ANG II:ANG I, an index of ACE activity in vivo, showed a close agreement with changes in plasma ACE activity measured with FAPGG as substrate, but not with HHL as substrate. We conclude that measurement of ACE activity in vitro with FAPGG as substrate provides a reliable measure of changes in conversion of ANG I to ANG II in vivo during CEI therapy.

Possibilities of using fosinopril in treatment of patients with chronic kidney disease in combination with cardiovascular diseases and diabetes mellitus

2021 ◽  
pp. 17-25
Author(s):  
E. Yu. Ebzeeva ◽  
O. D. Ostroumova ◽  
S. V. Batyukina ◽  
N. A. Shatalova ◽  
N. M. Doldo ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Chronic Kidney Disease ◽  
Cardiovascular Diseases ◽  
Kidney Disease ◽  
Angiotensin Converting Enzyme ◽  
Enzyme Inhibitor ◽  
The Body ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors ◽  
Secondary Damage

Chronic kidney disease is one of the most common diseases in general medical practice, due to their secondary damage to the kidneys in arterial hypertension, chronic heart failure, and diabetes mellitus. The coexistence of hypertension and diabetes increases the likelihood of developing chronic kidney failure tenfold. In turn, chronic kidney disease is an important independent risk factor for the development of cardiovascular complications, including fatal ones, due to the direct relationship of the pathogenetic mechanisms of cardiorenal relationships. Approaches to the treatment of chronic kidney disease should be aimed both at preventing the risks of developing renal dysfunction, and at treating existing pathology. The multifactorial nature of the disease and the complex etiopathogenetic relationships determine the need to optimize existing approaches to the treatment of chronic kidney disease in multimorbidity patients with concomitance cardiovascular diseases and diabetes mellitus. This is also due to the fact that, unlike other target organs, compensation for background disease does not always prevent further deterioration of kidney function. According to the recommendations of the main scientific communities, in such cases, it is advisable to start therapy with the most effective angiotensin-converting enzyme inhibitors that combine nephro-and cardioprotective effects and have a dual route of elimination from the body, which is especially important in multimorbidity, the aim to prevent polypharmacy, reduce the risk of drug interactions and, consequently, side effects. This article reviews the literature data indicating the high efficacy and safety of the angiotensin converting enzyme inhibitor fosinopril in patients with chronic kidney disease in combination with cardiovascular diseases and diabetes mellitus.

An experimental study of the effect of zinc on the activity of angiotensin converting enzyme in serum.

1985 ◽  
Vol 31 (4) ◽  
pp. 581-584 ◽  
Author(s):  
P G Reeves ◽  
B L O'Dell
Keyword(s):  
Experimental Study ◽  
Angiotensin Converting Enzyme ◽  
Zinc Concentration ◽  
Converting Enzyme ◽  
Dietary Zinc ◽  
Assay Mixture ◽  
The Mean ◽  
Ace Activity

Abstract The activity in serum of zinc-dependent angiotensin converting enzyme (ACE), is measured to aid in diagnosis and monitor treatment of certain diseases. This report shows the effect of dietary zinc deprivation on ACE activity in the serum of rats. The mean (and SE) of the zinc concentration (mumol/L) in serum was 3.5 (0.3) in rats deprived of dietary zinc for four days, 16.3 (0.2) in control rats, and 19.8 (0.9) in rats deprived of zinc for four days, then repleted with zinc for 12 h. The respective mean (and SE) of ACE activities (nmol/mL per min) in serum were 390 (15), 543 (13), and 545 (20). Serum ACE activity was restored also by adding zinc to the assay mixture in vitro. The Vmax for ACE was 1.4 times greater when serum was diluted 40-fold as compared with twofold dilution. There was a small effect on the Km for the substrate, but the Km for zinc was decreased by 22-fold when serum was diluted 40-fold. The Vmax under these conditions was decreased by only 9%.

Angiotensin Converting Enzyme Activity in Human Serum: Relationship to Enzyme Inhibitor In Vivo and In Vitro

1982 ◽  
Vol 127 (2) ◽  
pp. 396-396
Author(s):  
B.N. Swanson ◽  
M. Hichens ◽  
P. Mojaverian ◽  
R.K. Ferguson ◽  
P.H. Vlasses ◽  
...  
Keyword(s):  
Enzyme Activity ◽  
Angiotensin Converting Enzyme ◽  
Human Serum ◽  
Enzyme Inhibitor ◽  
Converting Enzyme ◽  
Angiotensin Converting Enzyme Activity

scholarly journals Angiotensin-Converting Enzyme Inhibitors Reduce Uterine Fibroid Incidence in Hypertensive Women

2020 ◽  
Author(s):  
Nicole M Fischer ◽  
Tim O Nieuwenhuis ◽  
Bhuchitra Singh ◽  
Gayane Yenokyan ◽  
James H Segars
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Enzyme Inhibitor ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
The United States ◽  
Population Based ◽  
Research Database ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors

Absctract Context In vitro and in vivo evidence has supported the role of angiotensin II blockade in reducing leiomyoma cell proliferation and growth. However, no population-based study to date has investigated this potential association. Objective This work aims to determine whether prior angiotensin-converting enzyme inhibitor (ACEi) use is associated with a reduced odds of leiomyoma development. Design A nested case-control study was conducted. Setting The population was assembled from the Truven Health MarketScan Research Database, which includes private health insurance claims from January 1, 2012 to December 31, 2017. Patients or Other Participants We included (n = 353 917) women age 18 to 65 with hypertension. Cases (n = 13 108) with a leiomyoma diagnosis were matched to controls (n = 340 808) with no such diagnosis at a 1:26 ratio by age and region of origin within the United States. Intervention Prior ACEi use was determined from outpatient drug claims. Main Outcome Measure Leiomyoma development was indicated by a first-time diagnosis code. Results Women on an ACEi experienced a 31.8% reduced odds of developing clinically recognized leiomyoma compared to nonusers (odds ratio [OR] 0.68; 95% CI, 0.65-0.72). This association was significant for each age group: 30 to 39 years (OR 0.86; 95% CI, 0.74-0.99), 40 to 49 years (OR 0.71; 95% CI, 0.66-0.76), 50 to 59 years (OR 0.63; 95% CI, 0.58-0.69), and 60 to 65 years (OR 0.58; 95% CI, 0.50-0.69). Of the ACEis, lisinopril (OR 0.67; 95% CI, 0.64-0.71), quinapril (OR 0.62; 95% CI, 0.41-0.92), and ramipril (OR 0.35; 95% CI, 0.23-0.50) demonstrated a significant association with reduced leiomyoma incidence. Conclusions ACEi use was associated with a reduced odds of developing clinically recognized leiomyoma in adult hypertensive women.

Hormonal influence on endothelial cell angiotensin-converting enzyme activity

1984 ◽  
Vol 247 (3) ◽  
pp. C163-C168 ◽  
Author(s):  
A. H. Krulewitz ◽  
W. E. Baur ◽  
B. L. Fanburg
Keyword(s):  
Endothelial Cells ◽  
Angiotensin Converting Enzyme ◽  
Protein Content ◽  
Hormonal Regulation ◽  
Converting Enzyme ◽  
Cell Counts ◽  
Ace Activity ◽  
Sites Of Action ◽  
Culture Supernatants

The influence of various hormones on angiotensin-converting enzyme (ACE) production and release by bovine endothelial cells in culture was studied. Dexamethasone, thyroxine (T4), and triiodothyronine (T3) stimulated ACE activity in cells and their culture supernatants without affecting cell number or protein content. The stimulating effects of dexamethasone and thyroid hormones were additive, suggesting that these hormones may have different sites of action. In addition, their stimulating effects were blocked by cycloheximide, indicating that increased enzymatic activity occurred through new protein synthesis. The exposure of cells to insulin reduced ACE activity of cells and their culture supernatants without influencing cell counts or protein content; insulin also partially inhibited the stimulation of ACE activity by dexamethasone or T3. Our studies suggest that the production of ACE by endothelial cells is under hormonal regulation. Release of ACE activity into culture supernatants parallels changes in cellular ACE activity. The results supplement previous observations made in vitro and in vivo.

Sign in / Sign up

Export Citation Format

Share Document